CytomX Therapeutics Inc Dossier
Qualitative Analysis
Business overview
CytomX Therapeutics, Inc. is a clinical-stage, oncology-focused biopharmaceutical company pioneering the field of conditionally activated, masked biologics localized to the tumor microenvironment. Powered by its proprietary PROBODY therapeutic platform, the company designs safer, more effective therapies across multiple treatment modalities, including antibody-drug conjugates (ADCs), cytokines, and T-cell engagers. Its lead clinical-stage pipeline assets include varsetatug masetecan (Varseta-M; CX-2051), a masked EpCAM-directed ADC armed with a topoisomerase-1 inhibitor payload, and CX-801, a masked interferon alpha-2b PROBODY cytokine. CytomX maintains strategic research collaborations with major industry leaders, including Bristol Myers Squibb, Amgen, Regeneron, and Moderna.
Research as of 19 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
Focusing corporate resources and clinical development efforts on advancing varsetatug masetecan (Varseta-M; formerly CX-2051), a first-in-class EpCAM-directed antibody-drug conjugate (ADC) armed with a topoisomerase-1 inhibitor payload, as a company-building asset.
Expected impact: Establish clinical proof-of-concept and secure a regulatory pathway for a highly differentiated ADC targeting previously undruggable EpCAM-expressing solid tumors.
Leveraging the PROBODY therapeutic platform to design and develop conditionally active bispecific T-cell engagers and immunotherapies that localize drug activity to the tumor microenvironment, minimizing systemic toxicity.
Expected impact: Broaden the therapeutic window of bispecific cancer immunotherapies and generate substantial milestone and royalty revenue streams.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Strategic Partnerships
High
Terms: In June 2026, the collaboration was expanded to include up to 10 targets total. Regeneron paid an additional $37 million upfront, increasing the potential transaction value from $2 billion to approximately $4 billion in target nomination fees, research, development, regulatory, and commercial milestones, plus tiered global net sales royalties.
Medium
Terms: Agreement entered in 2023 to create mRNA-based conditionally activated therapies. CytomX received a $35 million upfront payment (including $5 million pre-paid research funding) and is eligible for up to $1.2 billion in future milestones plus tiered royalties. Work is currently paused pending future alignment.
Medium
Terms: Collaboration focused on T-cell-engaging bispecific therapeutics. CytomX received a $40 million upfront payment and Amgen purchased $20 million of CytomX common stock. CytomX is eligible for up to $950 million in additional upfront and milestone payments plus royalties. In 2025, the partners jointly decided to stop development of lead candidate CX-904, but Amgen retains exclusive rights to up to three additional undisclosed targets.